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a b s t r a c t
Cardiac progenitor cells including c-kit+ cells and cardiosphere-derived cells (CDCs) play important roles in cardiac repair and regeneration. CDCs were reported to contain only small subpopulations of c-kit+ cells and recent
publications suggested that depletion of the c-kit+ subpopulation of cells has no effect on regenerative properties
of CDCs. However, our current study showed that the vast majority of CDCs from murine heart actually express ckit, albeit, in an intracellular and non-glycosylated form. Immunostaining and ﬂow cytometry showed that the
ﬂuorescent signal indicative of c-kit immunostaining signiﬁcantly increased when cell membranes were permeabilized. Western blots further demonstrated that glycosylation of c-kit was increased during endothelial differentiation in a time dependent manner. Glycosylation inhibition by 1-deoxymannojirimycin hydrochloride (1DMM) blocked c-kit glycosylation and reduced expression of endothelial cell markers such as Flk-1 and CD31
during differentiation. Pretreatment of these cells with a c-kit kinase inhibitor (imatinib mesylate) also attenuated Flk-1 and CD31 expression. These results suggest that c-kit glycosylation and its kinase activity are likely needed for these cells to differentiate into an endothelial lineage. In vivo, we found that intracellular c-kit expressing
cells are located in the wall of cardiac blood vessels in mice subjected to myocardial infarction. In summary, our
work demonstrated for the ﬁrst time that c-kit is not only expressed in CDCs but may also directly participate in
CDC differentiation into an endothelial lineage.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Studies have shown that progenitor cells exist in adult hearts, including aged and diseased hearts (Mercola et al., 2011; Olson and
Schneider, 2003). Different types of cardiac progenitor cells were discovered including c-kit+, Sca-1+, Islet-1+, SSEA-1+ cells, as well as
side population and cardiosphere-derived cells (CDCs) (Nigro et al.,
2015). Animal and clinical studies have shown that c-kit+ cells and
CDCs play important roles in cardiac repair and regeneration (Leri
et al., 2015; Marban and Cingolani, 2012; Ellison et al., 2013;
Hariharan et al., 2015; Fransioli et al., 2008). C-kit+ progenitor cells
were ﬁrst identiﬁed in rat cardiac tissues (Beltrami et al., 2003). Despite
debate on the role of c-kit+ cells in myogenesis (Leri et al., 2015;
Goldstein et al., 2015; van Berlo et al., 2014), c-kit protein expression
is the most recognized progenitor cell marker. CDCs were initially isolated from human and murine cardiac tissue (Messina et al., 2004) and
⁎ Corresponding author at: University of Toledo, College of Medicine and Life Sciences,
Department of Medicine, Cardiology Division, Health Science Campus, Mail Stop 1025,
3000 Arlington Ave., Toledo, OH 43614-2598, USA.
E-mail address: Jiang.Tian@utoledo.edu (J. Tian).

were introduced as a candidate progenitor cell for regenerative therapy
after myocardial infarction (MI) (Smith et al., 2007). Clinical trials such
as CADUCEUS (Makkar et al., 2012) demonstrated that injection of CDCs
improved cardiac function and increased viable tissue in patients with
MI. Finally, it was reported that CDCs contain a small subpopulation of
c-kit+ cells, ranging from ~ 1% to ~ 25% (Messina et al., 2004; Smith
et al., 2007; Cheng et al., 2014).
C-kit protein, ﬁrst identiﬁed as a virus proto-oncogene, v-kit (Besmer
et al., 1986), is a tyrosine kinase and a receptor for stem cell factor (SCF),
containing nine N-glycosylation sites in its sequence (Nigro et al., 2015;
Yarden et al., 1987). It is known that c-kit undergoes N-linked glycosylation in the endoplasmic reticulum (ER) before being transported to the
Golgi apparatus where it is modiﬁed by further complex glycosylations
and subsequently transported to the cell surface (Aebi, 2013). Two
forms of c-kit protein, a non-glycosylated form (~100–120 kDa) and a
glycosylated form (~140 kDa), were detected previously in cancer cells
(Blume-Jensen et al., 1991; Rubin et al., 2001; Schmidt-Arras et al.,
2005). In studies of cardiac progenitor cells, cellular distribution and glycosylation of c-kit have not been evaluated.
Increased c-kit+ cell number was observed in different disease
states, and conditional knockout of c-kit was found to abolish cardiac

http://dx.doi.org/10.1016/j.scr.2016.04.017
1873-5061/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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regeneration in experimental heart failure (Ellison et al., 2013; Ellison
et al., 2007). Our previous study also showed that c-kit+ cells were increased in cardiac tissue from mice with chronic kidney disease, particularly in transgenic mice with reduced Na/K-ATPase-Src mediated
signaling capability (Drummond et al., 2014). However, the speciﬁc
role of c-kit protein and its regulatory mechanism in these progenitor
cells remain elusive. The current work studied c-kit expression and its
potential role in cardiac progenitor cell differentiation into an endothelial lineage.
2. Materials and methods
2.1. Animals
Animal experiments were conducted in accordance with the National Institutes of Health, Guide for the Care and Use of Laboratory Animals
under protocols approved by the Institutional Animal Care and Use
Committee at the University of Toledo. Mice from an inbred C57BL6/J
strain (Moseley et al., 2004) were maintained at the University of Toledo. Adult male mice which were two months of age were used for isolation of cardiosphere-derived progenitor cells and for myocardial
infarction experiments.

mouse endothelial cell culture medium (MECM, Cell Biologics Inc., Chicago, IL, Cat. No.: M1168) to start endothelial differentiation. For immunostaining, CDCs were allowed to attach to coverslips in CGM overnight,
at which point the media was changed to MECM to start endothelial differentiation. MECM was changed every two days during differentiation
until cells were collected for Western blot or immunostaining. Following the start of endothelial differentiation cells were collected on days
1, 3, 7, 10, 14, 21, and 28.
For inhibition of N-glycosylation in CDCs, 1-deoxymannojirimycin
hydrochloride (1-DMM, Sigma-Aldrich, Cat. No.: D9160), an inhibitor
of N-linked glycosylation, was added to MECM at 5, 50 and 500 μM concentrations during induction of endothelial differentiation. CDCs in
MECM without 1-DMM were used as control. The induction media
was changed every two days. Cells were collected on day 7 and 14 for
Western blot.
Speciﬁc inhibition of c-kit kinase activity was achieved through the
use of the c-kit tyrosine kinase inhibitor imatinib mesylate
(Selleckchem, Cat. No.: S1026) which was was added to MECM at 0.1,
0.2, 0.5, 1, 2, 5, and 10 μM concentrations during the 14 day endothelial
differentiation induction period. Cells treated with MECM alone without
imatinib mesylate were used as controls. The induction media was
changed every two days. Cells were collected on day 14 for Western
blot.

2.2. Isolation of cardiac progenitor cells
2.4. Immunocytochemistry
Cardiosphere-derived cells (CDCs) were obtained following procedures previously described (Messina et al., 2004; Smith et al., 2007)
with minor modiﬁcations. Brieﬂy, gross connective tissue was removed
by blunt dissection to obtain pure mouse heart muscle tissue, which was
then cut into small explants (~1 mm in dimension). The explants were
washed and partially digested enzymatically with 0.025% Trypsin/0.01%
ethylenediaminetetraacetic acid (EDTA. Gibco Inc., Grand Island, NY,
Cat. No.: R001-100) for 10 min. The explants were then cultured on
dishes coated with ﬁbronectin (Santa Cruz Inc., Santa Cruz, CA, Cat.
No.: sc-29011) in complete explant medium (CEM), which contains:
500 mL Iscove's Modiﬁed Dulbecco's Medium (IMDM, Gibco Inc., Cat.
No.: 12440), 125 mL Fetal bovine serum (FBS) (Gibco Inc., Cat. No.:
10437), 1% penicillin–streptomycin (Mediatech Inc., Manassas, VA,
Cat. No.: 30-002-Cl), 1 mmol/L L-glutamine (Gibco Inc., Cat. No.:
25030), and 1 mmol/L 2-mercaptoethanol (Sigma-Aldrich, St. Louis,
MO, Cat. No.: M6250). After 14 days, a layer of stromal-like cells grew
out of adherent explants, over which small, round, phase-bright cells
migrated. These phase-bright cells were harvested by sequential
Versene (Gibco Inc., Cat. No.: 15040) and 0.025% Trypsin-0.01% EDTA digestion and seeded on poly-D-lysine coated (Sigma-Aldrich, Cat. No.:
P6407) dishes in cardiosphere growth medium (CGM) that contains:
175 mL IMDM, 325 mL DMEM/F12 (Gibco Inc., Cat. No.: 11330), 3.5%
FBS, 1% penicillin–streptomycin, 1 mmol/L L-glutamine, 2% B27 supplement (Gibco Inc., Cat. No.: 17504), 1 mmol/L 2-mercaptoethanol,
80 ng/mL basic Fibroblast growth factor (bFGF, PeproTech Inc., Rocky
Hill, NJ, Cat. No.: AF-450-33), 25 ng/mL epidermal growth factor (EGF,
PeproTech Inc., Cat. No.: 315-09), 4 ng/mL cardiotrophin-1 (PeproTech
Inc., Cat. No.: 250-25), 1 unit/mL α-Thrombin (Haemtech Inc., Essex
Junction, VT, Cat. No.: HCT-0020). The seeded cells formed
cardiospheres on poly-D-lysine coated dishes following 7 to 21 days.
Subsequently, the cardiosphere forming cells were collected and plated
on ﬁbronectin-coated dishes in CGM where they expand as monolayers.
CDCs were expanded and stocks were collected and stored in liquid nitrogen for later experiments.
2.3. Inducing endothelial lineage differentiation of CDCs
CDCs at the 5th–15th passages were used for endothelial differentiation. CDCs were seeded on matrigel-coated dishes or glass coverslips.
For Western blotting, CDCs grew in CGM for three days at which time
they reached 80% conﬂuence. Then media was changed to complete

Cells were ﬁxed in 3% paraformaldehyde. Following ﬁxation, cells
were washed with 1 × Dulbecco's phosphate buffered saline (DPBS;
Gibco, Cat. No: 14190-144) three times and were then blocked with
2% Bovine Serum Albumin (BSA; Sigma-Aldrich Inc., Cat. No: A4503)
in DPBS containing 0.3% Triton X-100 (DPBS-Tr) for 1 h at room temperature. Subsequently, cells were incubated with primary antibodies diluted in blocking buffer in a humidiﬁed chamber overnight at 4 °C.
The next day, cells were washed three times with DPBS-Tr. Cells were
then incubated with secondary antibodies diluted in blocking buffer at
room temperature for 1.5 h. Following incubation with secondary antibody, the cells were washed with DPBS-Tr one time. Cells were then incubated with 4′,6-diamidino-2-phenylindole (DAPI, Life Technologies
Inc., Cat. No.: D1306) solution for 5 min and were washed three times
in DPBS-Tr. The coverslips were then mounted with Prolong Gold
anti-fade reagent (Life Technologies Inc., Cat. No.: 36,930). Immunoﬂuorescence was visualized on a confocal microscope (TCS SP5 LCSM,
Leica, Buffalo Grove, IL).
The primary antibodies used in immunostaining include: anti-c-kitFITC antibody, 1:100 dilution (Abcam Inc., Cambridge, MA, Cat. No.:
ab24870); rabbit anti-CD31, 1:20 dilution (Abcam Inc., Cat. No.:
ab28364); mouse anti-Flk-1, 1:50 dilution (Santa Cruz Inc., Cat. No.:
sc-6251); rat anti-CD90, 1:100 dilution (Abcam Inc., Cat. No.: ab3105);
rat anti-mouse CD105, 1:50 dilution (R&D Systems, Minneapolis, MN,
Cat. No.: MAB1320); rabbit anti-Oct3/4, 1:200 dilution (Santa Cruz
Inc., Cat. No.: sc-9081); rabbit anti-Nanog, 1:200 dilution (Santa Cruz
Inc., Cat. No.: sc-33760); rabbit anti-Nkx2.5, 1:400 dilution (Abcam
Inc., Cat. No.: ab22611); rabbit anti-GATA4, 1:200 dilution (Santa Cruz
Inc., Cat. No.: sc-9053); mouse anti-α-actinin, 1:1000 dilution (SigmaAldrich Inc., Cat. No.: A7811); rabbit anti-cardiac troponin I, 1:100 dilution (Abcam Inc., Cat. No.: ab47003); rabbit anti-α-smooth muscle
actin, 1:500 dilution (Abcam Inc., Cat. No.: ab5694); chicken antivimentin, 1:200 dilution (Abcam Inc., Cat. No.: ab24525); rat antimouse CD31, 1:100 dilution (AbD Serotec Inc., Cat. No.: MCA2388GA).
The secondary antibodies included: goat anti-rabbit IgG (H + L),
Alexa Fluor 594 conjugate (Life Technologies Inc., Cat. No.: A-11012);
goat anti-mouse IgG (H + L), Alexa Fluor 594 conjugate (Life Technologies Inc., Cat. No.: A-11005); goat anti-mouse IgG (H + L), Alexa Fluor
488 conjugate (Life Technologies Inc., Cat. No.: A-11001); goat anti-rat
IgG (H + L), Alexa Fluor 488 conjugate (Life Technologies Inc., Cat.
No.: A-11006); goat anti-chicken IgG (H + L), Alexa Fluor 647 conjugate
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(Life Technologies Inc., Cat. No.: A-21449). Secondary antibodies were
all used at 1:600–1:800 dilutions.
2.5. Flow cytometry
CDCs were grown in a ﬁbronectin-coated 75 cm2 ﬂask. Once the cells
reached 80% conﬂuence they were collected and prepared for ﬂow cytometry, brieﬂy as follows: CDCs were washed with DPBS twice, then
incubated with 5 mL Versene at 37 °C with 5% CO2 for 10 min. Detached
cells were suspended in CGM and centrifuged at 2000 × g for 5 min.
Pelleted cells were washed once with 12 mL FACS buffer (DPBS containing 2% BSA). Washed cells were then suspended in 3 mL of 1.5% paraformaldehyde solution and rotated at room temperature for 10 min for
ﬁxation. Following ﬁxation cells were washed once with 12 mL FACS
buffer and suspended in fresh FACS buffer. For membrane permeabilization, ﬁxed cells were incubated with FACS buffer containing
0.1% Triton X-100 for 5 min. Anti-c-kit-FITC antibody (Abcam Inc., Cat.
No.: ab24870), 1:200 dilution, was then added to the cell suspension
and incubated on ice for 30 min in the dark. Non-permeabilized cells
were directly incubated with antibody without Triton X-100. After antibody incubation, cells were washed twice with FACS buffer and resuspend in 1 mL FACS buffer. Flow cytometry was performed on a
Becton-Dickinson FACSCalibur Flow Cytometer (Becton-Dickinson, San
Jose, CA). Cells that were not permeabilized and not incubated with antibody were used as negative control.
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overnight at 4 °C. After washing, membranes were incubated with
appropriate secondary antibodies. Clarity Western ECL substrate (BioRad Inc., Cat. No.: 170-5060) was used for chemiluminescence detection on an Omega Lum™ G imaging system (Aplegen Inc., San
Francisco, CA).
The primary antibodies used in Western blot analyses were: rabbit
anti-c-kit antibody, 1:500 dilution (Abcam Inc., Cat. No.: ab5506); rat
anti-mouse CD31, 1:1000 dilution (AbD Serotec Inc., Raleigh, NC, Cat.
No.: MCA2388GA); mouse anti-Flk-1, 1:1000 dilution (Santa Cruz Inc.,
Cat. No.: sc-6251); rabbit anti-glucose transporter GLUT3 antibody,
1:10,000 dilution (Abcam Inc., Cat. No.: ab191071); rabbit anti-c-kit
(phospho Y568 + Y570) antibody 1:10,000 dilution (Abcam Inc., Cat.
No.: ab5616); rabbit anti-c-kit (phospho Y730) antibody 1:5000 dilution (Abcam Inc., Cat. No.: ab5633); goat anti-β-actin antibody,
1:1000 dilution (Santa Cruz Inc., Cat. No.: sc-1616); rabbit antiGAPDH antibody, 1:1000 dilution (Santa Cruz Inc., Cat. No.: sc25778). Secondary antibodies included goat anti-rabbit IgG-HRP
(Santa Cruz Inc., Cat. No.: sc-2030); goat anti-mouse IgG-HRP (Santz
Cruz Inc., Cat. No.: sc-2031); donkey anti-goat IgG-HRP (Santa Cruz
Inc., Cat. No.: sc-2020); chicken anti-rat IgG-HRP (Santa Cruz Inc., Cat.
No.: sc-2956). Secondary antibodies were used at a concentration
which was half the concentration of the speciﬁc primary antibody
being used.

2.8. Myocardial infarction (MI)
2.6. RNA isolation and reverse transcription-quantitative polymerase chain
reaction (RT-qPCR)
CDCs were collected in 350 μL of lysis buffer RLT to begin isolation
of total RNA using the RNeasy mini kit (Qiagen Inc., Carol Stream, IL,
Cat. No.: 217004), according to the instructions provided by the manufacturer. Immediately following RNA isolation, cDNA was synthesized
for mRNA brieﬂy as follows: cDNA was synthesized using the RT2 First
Strand cDNA Synthesis Kit from Qiagen according to the
manufacturer's protocol using 1 μg total RNA as input (Qiagen Inc.,
Cat. No.: 330404). Following reverse transcription cDNA was diluted
according to the manufacturer's protocol for storage at − 20 °C and
later use in qPCR.
To determine the level of c-kit gene expression, Gapdh was used as
an internal control. We also compared the expression of c-kit with Na/
K-ATPase α1 gene (Atp1a1), a ubiquitously expressed gene in all mammalian cells. RT2 qPCR primer assays for mouse c-kit (Cat. No.:
PPM05195A-200), Atp1a1 (Cat. No.: PPM04163A-200, and Gapdh
(Cat. No.: PPM02946E-200) were purchased from Qiagen Inc. and
were used in the RT2 SYBR Green qPCR reaction mix (Qiagen Inc., Cat.
No.: 330529) according to the manufacturer's protocol. Reactions
were carried out on an ABI 7500 Fast platform (Life Technologies, Boston, MA) using the following cycling program: 10 min incubation at
95 °C, [95 °C for 15 s, 60 °C for 1 min (Fluorescence detection performed)] repeated 40 times. A determination of mRNA expression was
conducted by comparing the relative change in cycle threshold value
(ΔCt) from the internal control, GAPDH.
2.7. Western blot analysis
Western blots were carried out as described previously
(Drummond et al., 2014; Elkareh et al., 2007; Li et al., 2011). Cell lysates were collected in radio-immunoprecipitation assay (RIPA) buffer
(Santa Cruz Inc., Cat. No.: sc-24948) containing protease inhibitors and
phosphatase inhibitors. Electrophoretic separation of protein was performed on 8% Tris/glycine SDS-polyacrylamide gels and separated proteins were then transferred to 0.45 μm nitrocellulose blotting
membrane. Membranes were blocked with 5% non-fat dry milk or 5%
BSA for 1 h at room temperature. Membranes were then incubated
with speciﬁc primary antibodies suspended in blocking buffer

Acute MI was induced as previously described (Virag and Lust,
2011). Brieﬂy, mice were anesthetized with 2% isoﬂurane, intubated
endotracheally with a 22 gauge intravenous catheter and placed in a supine position on the warming surgery platform. Mice were ventilated
using a mouse ventilator (Minivent Type845, Hugo Sachs Elektronik,
Germany) to control respiration with tidal volume setting at 0.25 mL
at a rate of 150 strokes/min. Prior to surgery hair was removed and
the surgical area cleaned and sterilized. Subsequently, a thoracotomy
was performed in the fourth intercostal space through an incision
made in the left side of the chest. After displacing the pericardium, a
permanent ligation of the left anterior descending artery (LAD) was
conducted 2 mm below the left atrium with a 6-0 silk suture (Cat. No.:
Coviden S-1750-K; esutures.com, Mokena, IL) under a dissecting microscope (Olympus SZX-7; B&B Microscopes Ltd., Pittsburgh, PA). Successful MI was veriﬁed via epicardial blanching. Following successful
surgery mice were kept for 3 weeks before euthanization and organ
collection.

2.9. Immunohistochemistry
Left ventricle sections were immediately ﬁxed in 4% formaldehyde
buffer solution (pH 7.2) after dissection, and parafﬁn embedded after
48 h of ﬁxation. The tissues were then cut to a thickness of 4 μm and
mounted onto microscopy slides. Slides were subjected to immunoﬂuorescence staining for c-kit and CD31 in a manner similar to previous experiments (Drummond et al., 2014). The mounted parafﬁn embedded
tissue sections were ﬁrst deparafﬁnized with xylene and rehydrated
by sequential incubations in ethanol and water. Following rehydration,
antigen retrieval, blocking and antibody incubation were performed sequentially. Slides were then mounted with anti-fade gold from Life
Technologies Inc. Immunoﬂuorescence was visualized under a using
confocal microscopy.

2.10. Statistical analysis
Data were presented as Mean ± SEM. One way ANOVA or t-test was
used for analysis of signiﬁcance.
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3. Results
3.1. Intracellular expression of c-kit protein in isolated CDCs
We isolated CDCs from mice with a C57BL6/J background and characterized the cells based on previous publications (Smith et al., 2007;
Cheng et al., 2014). Representative images of cardiac explant migration,
cardiosphere formation, and ampliﬁed CDCs are shown in Fig. 1A. To
further characterize the isolated CDCs, immunostaining was performed
using antibodies against progenitor cell markers and different lineage
markers. As shown in Fig. 1B, CDCs are positive for progenitor cell

markers such as NKx2.5, GATA4, Oct3/4 and Nanog. These cells are
also CD105 positive but CD90 negative, which is consistent with published data on these cells (Smith et al., 2007; Cheng et al., 2014). In contrast, as shown in Fig. 1C, markers for endothelial cells, smooth muscle
cells, and cardiomyocytes viz., CD31, α-SMA, α-actinin, and cardiac troponin I, were negative. However, CDCs were positive for the cardiac ﬁbroblast marker, vimentin. The immunostaining in Fig. 1A was done
after cell membrane permeabilization.
To check if these cells express c-kit and its cellular location, we used
an anti-c-kit-FITC antibody from Abcam under conditions with or without membrane permeabilization. As shown in Fig. 2A, the ﬂuorescent

Fig. 1. Characterization of murine cardiosphere-derived cells (CDCs). (A): Shows the process of CDC isolation from 2-month old adult male mouse hearts. Cardiac muscle explants (1 mm
dimension) were plated on ﬁbronectin-coated petri dishes. Bright-phase cells migrating out of the explants were collected and seeded on poly-D-lysine coated dishes to form
cardiospheres. Cardiospheres were then collected and seeded on ﬁbronectin-coated dishes to grow as a monolayer. (B): Shows the expression of progenitor cell markers: Nkx2.5,
GATA4, Oct3/4, and Nanog; CDC markers reported from literature: CD90 and CD105; and different lineage markers: CD31, α-SMA, α-actinin, cardiac troponin I (cTnI), and vimentin in
isolated CDCs. DAPI was used to for nuclear staining in these cells.
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Fig. 2. Intracellular expression of c-kit in CDCs. (A): Immunostaining of c-kit in CDCs was performed using anti-c-kit-FITC antibody (the same antibody as ﬂow cytometry). Cultured CDCs
were ﬁxed with 3% paraformaldehyde and then incubated with anti-c-kit-FITC antibody with or without membrane permeabilization. Cells which were not permeabilized and not
incubated with antibody were used as negative control. Fluorescent images were taken under a Leica Confocal microscope using a 20× or a 63× lens. DAPI (purple) was used for
nuclear staining; (B): Flow cytometry of CDCs indicates that a majority of c-kit expression in CDCs is intracellular. CDCs were ﬁxed with 1.5% paraformaldehyde and stained with antic-kit-FITC antibody under conditions of non-permeabilization (blue curve in the merged ﬁgure) or permeabilization with 0.1% Triton X-100 (orange curve). Cells with ﬁxation only
were used as negative control (red curve); (C): Western blot of c-kit expression in CDCs in different passages. Cell lysate of CDCs were collected in RIPA buffer and probed for c-kit
using Western blot. A porcine epithelial cell line, LLC-PK1, was used as negative control; (D): c-kit gene expression and Na/K-ATPase α1 gene (Atp1a1) expression measured by qPCR,
Gapdh was used as internal control. ΔCTc-kit = CTc-kit − CTGAPDH and ΔCTATP1A1 = CTATP1A1 − CTGAPDH. Higher ΔCT means lower expression level of the gene.
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signal obtained by immunostaining using this antibody was very weak
in cells without membrane permeabilization, but became much stronger when cell membranes were permeabilized. Using a 63 × oil lens,
our results clearly show that c-kit staining was mainly intracellular
(Fig. 2A). We also compared c-kit labeling using ﬂow cytometry with
or without membrane permeabilization. As shown in Fig. 2B, a population of c-kit+ cells with a weak ﬂuorescent signal (peak value at 102 arbitrary units) was observed when cells were labeled without cell
membrane permeabilization. However, if c-kit labeling was performed
following membrane permeabilization, the ﬂuorescent signal indicating
positive c-kit staining was about 10 times higher (peak value at 103 arbitrary units) than that in non-permeabilized cells, indicating that a vast
majority of the c-kit protein was expressed intracellularly in these cells.
We also collected cell lysates from different generations of CDCs and
probed for c-kit using Western blotting. A porcine proximal tubule somatic cell line (LLC-PK1) was used as negative control. As shown in
Fig. 2C, CDCs express c-kit protein up to at least the 20th generation,
while the negative control LLC-PK1 cells do not express c-kit protein.
This result conﬁrms that CDCs do express c-kit protein. However, the
observed c-kit protein was mainly found at ~ 100 kDa, corresponding
to a non-glycosylated form according to previous reports
(Blume-Jensen et al., 1991; Rubin et al., 2001).
To further conﬁrm the expression of c-kit in CDCs, we also performed qPCR using Gapdh as an internal control in addition to comparison with the Na/K-ATPase α1 gene (Atp1a1), a ubiquitously expressed
gene. As shown in Fig. 2D, c-kit gene expression was detected in CDCs,
though at relatively low levels. This measurement, together with the
immunostaining, ﬂow cytometry, and Western blot data, clearly indicate that c-kit protein is expressed in isolated CDCs.
3.2. Endothelial differentiation increased c-kit expression and glycosylation
in isolated CDCs
To examine c-kit expression and glycosylation status during differentiation, CDCs were cultured in endothelial differentiation medium
as described in the “Materials and methods” section for up to 28 days
while replenishing the medium every two days. Cell lysates were collected at the stem cell stage as well as at days 1, 3, 7, 10, 14, 21, and
28 after induction of endothelial differentiation. As shown in Fig. 3A,
Western blot analysis showed that CDCs without differentiation induction express mainly a non-glycosylated form of c-kit found at ~100 kDa,
whereas endothelial differentiation induced an additional ~ 140 kDa
band which represents glycosylated c-kit (Rubin et al., 2001;
Schmidt-Arras et al., 2005), in a time-dependent manner. The experiment also showed that endothelial differentiation induces expression
of the endothelial cell markers Flk-1 and CD31 with the same pattern
as glycosylated c-kit. Since c-kit glycosylation was increased after differentiation, we also probed glucose transporters. The results showed that
CDCs express glucose transporter 3 (GLUT3) and its expression had a
trend of increase during differentiation but was not statistically signiﬁcant until 28 days after initiation of endothelial differentiation (Fig. 3A).
We also probed for GLUT 1 and 4, but did not detect any changes in their
expression during differentiation (data not shown).
Immunostaining using anti-c-kit-FITC antibody was performed on
CDCs at different time points with membrane permeabilization. As
shown in Fig. 3B, endothelial differentiation induced signiﬁcant increases in c-kit as well as CD31 and Flk-1 from 7 to 14 days after induction. Fig. 3C showed high resolution images of these markers at different
time points.
3.3. Inhibition of glycosylation attenuates Flk-1 and CD31 expression during
endothelial differentiation in CDCs
To study if glycosylation is required for differentiation into endothelial cells, CDCs were cultured in endothelial differentiation medium
with or without 1-deoxymannojirimycin hydrochloride (1-DMM), an

N-glycosylation inhibitor. Since the time course study showed the
most dramatic change of c-kit glycosylation started at 7 to 14 days
after differentiation induction, we chose the time point of 7 and
14 days after induction to examine the effect of 1-DMM. As shown in
Fig. 4A, 1-DMM treatment reduced glycosylation of c-kit during the differentiation process. It also decreased the expression of endothelial cell
markers such as Flk-1 and CD31 in these cells, but it did not affect the
expression of GLUT3.
3.4. Inhibition of c-kit kinase activity by imatinib mesylate attenuated Flk-1
and CD31 expression during endothelial differentiation in CDCs
It is known that c-kit activation and phosphorylation occurs only
when it becomes glycosylated (Aebi, 2013). To further test if c-kit kinase
activity is required for CDC differentiation into an endothelial lineage,
we treated CDCs with different concentrations of imatinib mesylate (a
c-kit kinase inhibitor) during differentiation. As shown in Fig. 5, imatinib mesylate at 5 to 10 μM reduced c-kit phosphorylation. Additionally,
treatment with this kinase inhibitor also reduced Flk-1 and CD31 expression during endothelial differentiation.
3.5. C-kit+ cells are involved in blood vessel formation in vivo
We have shown above that CDCs can differentiate into endothelial
cells, and have enhanced c-kit expression levels. To further test if c-kit
expressing cells participate in the formation of blood vessels in animal
models, immunostaining for c-kit and the endothelial cell marker
CD31 was performed on left ventricle tissue isolated from mice subjected to myocardial infarction (MI). As shown in Fig. 6A, MI surgery significantly induced increases in c-kit cell number in addition to CD31
positive blood vessels in the infarcted zone 3 weeks following surgery.
More interestingly it was found that in sham-operated mice, about
80% of the blood vessels were CD31 positive (red color) and c-kit negative (green color), while a few vessels had c-kit positive cells (upper
panel of Fig. 6B). However, signals for both c-kit and CD31 were positive
in most of the blood vessels in the infarcted area of heart tissue following MI in mice (lower panel of Fig. 6B), indicating that cells expressing ckit may participate in blood vessel formation in response to MI. In these
vessels, c-kit expression was seen outside the nuclear, while CD31 signal was most abundant in the junction area between neighboring cells.
4. Discussion and conclusion
4.1. Intracellular expression of c-kit is a unique feature of cardiac progenitor
cells
Based on the data presented in our current study, we believe that the
low abundance of membrane-associated and the immature form in
which c-kit is expressed in CDCs is not a deﬁciency, but rather a unique
feature of cardiac progenitor cells. However, a critical question that
arises from this is: why does c-kit, a membrane receptor tyrosine kinase,
express intracellularly in an “immature” form in CDCs? C-kit protein can
be bound and activated by SCF when expressed on the plasma membrane (Lennartsson and Ronnstrand, 2012), and studies have shown
that SCF stimulates cell growth in erythroid progenitor cells (Amano
et al., 1993), in cerebral cortical cultures (Jin et al., 2002), and in
human glioblastoma cells (Berdel et al., 1992). In our experiments, ckit was mostly expressed in the cytosol of CDCs. Thus, c-kit in these progenitor cells likely does not function as a membrane receptor and cell
growth stimulator before it commits to an endothelial lineage. In essence, these features of c-kit expression may be a unique mechanism
that maintains CDC quiescence, preventing precocious responses to
changes in circulating SCF. Needless to say, this hypothesis needs
more sophisticated studies to be validated.
Our study revealed that the majority of CDCs express c-kit protein,
suggesting that a larger population of c-kit expressing cells may exist
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in cardiac tissue than previously indicated (Messina et al., 2004; Smith
et al., 2007; Cheng et al., 2014). The experimental results suggest that
c-kit is not only expressed in CDCs but may also directly participate in
regulation of CDC differentiation. Previous characterization of CDCs
found only a small population of c-kit+ cells (Messina et al., 2004;
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Smith et al., 2007; Cheng et al., 2014). However, since c-kit protein
was assumed to be a protein found on the cell surface, the determination of c-kit+ cell quantity was based on the method of magnetically activated cell sorting and ﬂow cytometry without permeabilizing the cell
membrane. Conversely, we used cell membrane permeabilization and

Fig. 3. Endothelial differentiation increases c-kit expression and its glycosylation in CDCs. (A): Endothelial differentiation of CDCs was initiated by changing growth medium of CDCs from
CGM to MECM. Cell lysates were collected at the stem cell stage and at days 1, 3, 7, 10, 14, 21, and 28 after differentiation induction. Expression of c-kit, CD31, Flk-1, and glucose transporter
3 (GLUT3) were probed using Western blot. (B): CDCs were ﬁxed and immunostained at the stem cell stage (before changing to differentiation medium) and at 7 and 14 days after
differentiation with membrane permeabilization. Fluorescent images were taken under a Leica Confocal microscope using a 20× lens. DAPI (purple) was used for nuclear staining. (C):
Higher resolution images (63× oil lens) of c-kit, CD31, and Flk-1 at different stage of differentiation. Data is presented as Mean ± SEM, n = 3 independent determinations, * indicates
signiﬁcant difference (p b 0.05) vs expression level at stem cell stage (CDCs), ** indicates p b 0.01.
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Fig. 3 (continued).

revealed that the majority of CDCs actually express intracellular c-kit
protein, which is immature and non-glycosylated, and the expression
can be increased and switches to the glycosylated form during endothelial differentiation. In addition, previous publications identiﬁed CDCs
and c-kit+ cells from cardiac tissue as two separate categories of progenitor cells. Our study suggests that CDCs and c-kit+ cells might belong
to the same population, but represent cells at different stages of activation. An early report compared the functional beneﬁt of unsorted CDCs
against magnetic bead-sorted c-kit+ cells and concluded that puriﬁed ckit+ cells were inferior to unsorted CDCs in infarcted hearts (Li et al.,

2012). A more recent publication further showed that depletion of ckit+ cells from CDCs did not affect the beneﬁcial properties of CDCs in
cardiac regeneration (Cheng et al., 2014). Given the fact that the majority of CDCs actually express intracellular c-kit protein before differentiation, based on our current study, these sorted or non-sorted cells might
represent different stages of the same population of progenitor cells,
which have different functional effects. Even if they represent two different populations, our results indicate that a large number of progenitor cells in cardiac tissue express c-kit protein, which can be further
regulated by stimulation of differentiation. Since these new ﬁndings
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Fig. 4. Inhibition of c-kit glycosylation attenuates endothelial differentiation of CDCs. CDCs were treated with the N-glycosylation inhibitor 1-deoxymannojirimycin hydrochloride (1DMM) at 5, 50, or 500 μM during endothelial differentiation. Cell lysates were collected 7 and 14 days following induction of endothelial differentiation to probe for c-kit, CD31, Flk-1,
and GLUT3 using Western blot. Data is presented as Mean ± SEM, n = 3 independent determinations, ** indicates signiﬁcant difference (p b 0.01) vs expression level at stem cell
stage (CDC); ! indicates signiﬁcant difference (p b 0.05) vs control that was not treated with 1-DMM; !! indicates signiﬁcant difference (p b 0.01) vs control that was not treated with
1-DMM.

re-characterize CDCs and re-deﬁne the population of c-kit positive cells,
we suggest to call these cells “c-kit expressing progenitor cells” to distinguish from the terms that are currently used in the literature for
CDCs and c-kit positive cells.
4.2. Glycosylation of c-kit may be a novel mechanism that regulates progenitor cell differentiation
C-kit has been identiﬁed as an important adult progenitor cell marker that is critical for regeneration in experimental heart failure (Nigro
et al., 2015; Ellison et al., 2013). However, the exact role of c-kit in regulating progenitor cell differentiation has not been well studied. The
data presented in the current study reveals that c-kit glycosylation
and its kinase activity may be required for CDC differentiation into an
endothelial lineage. We observed that inhibition of glycosylation by 1DMM blocked expression of endothelial cell markers such as Flk-1 and
CD31, while inhibition of c-kit kinase by imatinib mesylate also attenuates Flk-1 and CD31 expression, indicating the direct involvement of ckit in mediating endothelial differentiation in CDCs. However, it is not
clear what pathways are regulated during differentiation to trigger the
glycosylation process. Our experiments showed that GLUT3 expression
was increased during differentiation compared to non-differentiated
CDCs. GLUT3 is a glucose transporter with high afﬁnity to glucose and
is important during embryonic development (Tonack et al., 2006).

However, the role of GLUT3 in CDC differentiation needs to be further
studied.
CDCs and c-kit+ cells are both known to be able to differentiate into
endothelial cells (Marban and Cingolani, 2012; Patruno et al., 2014;
Fang et al., 2012). Our current study reveals that c-kit glycosylation is
an important process during endothelial differentiation. In addition to
CD31 and Flk-1, we also examined Von Willebrand Factor (VWF), a
commonly used marker for endothelial cells, using Western blot and
immunostaining. However, it did not show any speciﬁc signal. Given
that in vitro induction of an endothelial lineage is limited in that cell display endothelial qualities and markers but are not fully functional endothelial cells, we added the in vivo examination of c-kit expressing cells.
Indeed, we observed c-kit + cells located within the wall of blood
vessels, especially in infarcted areas of left ventricle tissue from
mice subjected to MI surgery, indicating the involvement of c-kit in
vascularization/angiogenesis.
In summary, the current study has re-classiﬁed the majority of the
CDC population as c-kit expressing progenitor cells and demonstrated
for the ﬁrst time that glycosylation is an important mechanism in regulating CDC differentiation into an endothelial lineage. These results, are
critical for understanding the early stages of cardiac progenitor cell regulation, and provide important information regarding the role of c-kit in
cardiac progenitor cells. The ﬁnding of c-kit glycosylation and its kinase
activity during CDC differentiation may serve as a potential target for
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Fig. 5. The c-kit kinase inhibitor imatinib mesylate inhibits endothelial differentiation of CDCs. CDCs were treated with c-kit tyrosine kinase inhibitor imatinib mesylate at 0, 0.1, 0.2, 0.5, 1,
2, 5, or 10 μM concentrations during the 14 day endothelial differentiation induction period. Cell lysates were collected 14 days following induction of endothelial differentiation to probe
for c-kit, CD31, Flk-1, phospho-c-kit (Y568 + Y570) and phospho-c-kit (Y730) using Western blot. Data is presented as Mean ± SEM, n = 3 independent determinations, ** indicates
signiﬁcant difference (p b 0.01) vs expression level of 14 day control.

regulating endogenous progenitor cell differentiation in disease conditions. Given the fact that direct injection progenitor cells has displayed
limited potential for engrafting and low expansion efﬁciency in the

treatment of cardiac failure after MI (Marban, 2014), discovery of mechanisms that regulate endogenous cardiac progenitor cells are critical for
future studies.
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Fig. 6. The c-kit expressing cells in cardiac blood vessels after myocardial infarction in mouse heart. Mouse heart was isolated and ﬁxed with 4% formaldehyde and immunostained with
anti-c-kit-FITC antibody and anti-CD31 antibody. Fluorescence signal was visualized using a Leica Confocal microscope with 63× oil lens. (A): The immunostaining of c-kit and CD31 in
non-infarcted area versus infarcted area. (B): Co-immunostaining of c-kit and CD31 in cardiac blood vessels from sham-operated mice (upper panel) and from the infarcted area of
mice subjected to MI surgery (lower panel).
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